Bamco Inc. NY Reduces Holdings in Genmab A/S (NASDAQ:GMAB)

Bamco Inc. NY lowered its stake in Genmab A/S (NASDAQ:GMAB) by 17.0% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 72,374 shares of the company’s stock after selling 14,779 shares during the quarter. Bamco Inc. NY’s holdings in Genmab A/S were worth $1,764,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in GMAB. Renaissance Technologies LLC raised its holdings in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock valued at $36,752,000 after buying an additional 103,859 shares during the last quarter. DDD Partners LLC purchased a new stake in shares of Genmab A/S during the second quarter worth about $8,860,000. Cubist Systematic Strategies LLC boosted its holdings in shares of Genmab A/S by 109.7% during the second quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock worth $7,000,000 after purchasing an additional 145,689 shares during the period. FMR LLC grew its stake in shares of Genmab A/S by 13.5% in the third quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in Genmab A/S by 6.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after purchasing an additional 14,165 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $21.70 on Wednesday. The stock has a 50 day moving average price of $22.55 and a 200 day moving average price of $25.46. The firm has a market capitalization of $14.36 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.68 and a beta of 0.96. Genmab A/S has a 52-week low of $20.34 and a 52-week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter last year, the business posted $0.47 earnings per share. As a group, sell-side analysts forecast that Genmab A/S will post 1.3 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on GMAB shares. Redburn Atlantic began coverage on Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a report on Wednesday, September 11th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.